NCT06994195View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Liposomal doxorubicin, Paclitaxel or Topotecan

Administration by intravenous infusion for a cycle of 4 weeks.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY